| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Benzyl isothiocyanate Benzyl isothiocyanate (BITC) is a naturally occurring aromatic isothiocyanate and electrophilic organosulfur phytochemical generated from the glucosinolate glucotropaeolin by myrosinase-mediated hydrolysis. Isothiocyanates (pid 476) is its parent chemical class. Natural dietary sources include nasturtium, garden cress, papaya and other plants containing benzyl glucosinolate. BITC has substantial mechanistic and animal anticancer evidence distinct from other isothiocyanates, particularly involving mitochondrial ROS generation, apoptosis, cell-cycle arrest and suppression of STAT3-dependent tumor signaling. It is not an approved anticancer drug and currently lacks convincing human cancer efficacy data. Primary mechanisms (ranked):
Bioavailability / PK relevance: BITC is orally absorbed and extensively metabolized through glutathione conjugation and the mercapturic-acid pathway. Human studies demonstrate urinary excretion of BITC-derived mercapturic-acid metabolites, with one oral study recovering approximately 54% of administered BITC as the major urinary metabolite and most excretion occurring within approximately 10–12 hours. After consumption of benzyl-glucosinolate-containing nasturtium, BITC metabolites and protein conjugates have been detected in plasma, urine and breath. Free BITC exposure is limited by rapid metabolism, chemical reactivity and protein conjugation. Pharmacokinetic characterization at proposed therapeutic anticancer doses remains inadequate. In-vitro vs systemic exposure relevance: Many anticancer experiments use BITC concentrations in the low-micromolar range, commonly approximately 2.5–10 µM. Some investigators describe low-micromolar concentrations as potentially plasma-achievable, but robust human pharmacokinetic data demonstrating sustained free BITC at concentrations used in cancer-cell experiments are lacking. Consequently, direct translation of prolonged in-vitro exposure to oral human dosing remains uncertain. Protein binding/conjugation and rapid mercapturic-acid metabolism further reduce freely available BITC. Clinical evidence status: Preclinical. There is extensive cancer-cell evidence and multiple animal studies demonstrating tumor-growth, angiogenesis and metastasis suppression. Human studies establish dietary absorption and metabolism but do not establish anticancer efficacy. No convincing completed clinical trial of BITC itself as a cancer treatment or chemopreventive intervention was identified. BITC should therefore be distinguished from phenethyl isothiocyanate (PEITC), which has entered human cancer-prevention trials. Safety / translation: Dietary exposure and use as a food flavouring are substantially different from pharmacologic anticancer dosing. JECFA concluded that BITC presented no safety concern at current flavouring-use exposure, but concentrated therapeutic exposure has not been adequately established as safe. BITC is highly electrophilic and concentrated material is an eye and respiratory irritant. Experimental genotoxic effects have been reported at concentrations or doses substantially above normal human dietary exposure. These findings support caution against extrapolating food-level safety to high-dose supplementation. Benzyl Isothiocyanate Mechanistic Profile
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| 9234- | AITC, | BITC, | PEITC, | Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines |
| - | in-vitro, | Bladder, | NA |
| 9228- | AITC, | BITC, | PEITC, | Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblasts |
| - | in-vitro, | Nor, | NA |
| 9190- | BITC, | Benzyl isothiocyanate suppresses high-fat diet-stimulated mammary tumor progression via the alteration of tumor microenvironments in obesity-resistant BALB/c mice |
| - | in-vivo, | BC, | 4T1 |
| 9162- | BITC, | Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 9192- | BITC, | Benzyl isothiocyanate: double trouble for breast cancer cells |
| - | in-vitro, | BC, | NA |
| 9195- | BITC, | Benzyl isothiocyanate inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model |
| - | in-vivo, | Pca, | NA |
| 9196- | BITC, | Benzyl Isothiocyanate Inhibits Epithelial-Mesenchymal Transition in Cultured and Xenografted Human Breast Cancer Cells |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PL45 |
| 9197- | BITC, | Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3 |
| - | in-vitro, | BC, | NA |
| 9198- | BITC, | Benzyl Isothiocyanate–Mediated Inhibition of Histone Deacetylase Leads to NF-κB Turnoff in Human Pancreatic Carcinoma Cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | Capan1 |
| 9199- | BITC, | Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways |
| - | in-vitro, | GC, | NA |
| 9200- | BITC, | p53 Independent Apoptosis by Benzyl Isothiocyanate in Human Breast Cancer Cells Is Mediated by Suppression of XIAP Expression |
| - | vitro+vivo, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 9201- | BITC, | Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | Capan-2 | - | in-vitro, | Nor, | HPDE-6 |
| 9202- | BITC, | Inhibition of Human Breast Cancer Xenograft Growth by Cruciferous Vegetable Constituent Benzyl Isothiocyanate |
| - | in-vivo, | BC, | MDA-MB-231 |
| 9203- | BITC, | Benzyl isothiocyanate inhibits tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in a BALB/c mouse xenograft model |
| - | vitro+vivo, | BC, | 4T1 |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| - | in-vitro, | CRC, | HT-29 |
| 9206- | BITC, | Inhibitory effects of benzyl isothiocyanate on the proliferation of prostate and breast cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 9207- | BITC, | Benzyl isothiocyanate–induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MCF-10AT |
| 9208- | BITC, | Benzyl Isothiocyanate-Induced DNA Damage Causes G2/M Cell Cycle Arrest and Apoptosis in Human Pancreatic Cancer Cells |
| - | in-vitro, | PC, | Capan-2 |
| 9209- | BITC, | ITCs, | SFN, | PEITC, | Effect of Isothiocyanates on Nuclear Accumulation of NF-κB, Nrf2, and Thioredoxin in Caco-2 Cells |
| - | in-vitro, | Colon, | Caco-2 |
| 9210- | BITC, | Potential mechanisms of benzyl isothiocyanate suppression of invasion and angiogenesis by the U87MG human glioma cell line |
| - | vitro+vivo, | GBM, | U87MG |
| 9211- | BITC, | Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species |
| - | in-vitro, | NSCLC, | NA |
| 9212- | BITC, | Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation by inducing apoptosis |
| - | in-vitro, | PC, | Panc02 | - | in-vitro, | PC, | MIA PaCa-2 |
| 9174- | BITC, | Benzyl isothiocyanate as an alternative to antibiotics? a comparative in vivo study using Pseudomonas aeruginosa |
| - | in-vivo, | Nor, | NA |
| 9161- | BITC, | Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | NA, | MCF10 |
| 9163- | BITC, | Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells |
| - | in-vitro, | PC, | Capan1 |
| 9164- | BITC, | Benzyl isothiocyanate induces reactive oxygen species-initiated autophagy and apoptosis in human prostate cancer cells |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| 9165- | BITC, | Anticancer activities of dietary benzyl isothiocyanate: A comprehensive review |
| - | Review, | Var, | NA |
| 9166- | BITC, | Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3 |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | Panc02 |
| 9167- | BITC, | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice |
| - | vitro+vivo, | BC, | 4T1 |
| 9168- | BITC, | Benzyl isothiocyanate suppresses development and metastasis of murine mammary carcinoma by regulating the Wnt/β‑catenin pathway |
| - | in-vitro, | BC, | 4T1 |
| 9169- | BITC, | CNOT2 /c-Myc/STAT3 signaling is critically involved in glycolysis mediated apoptosis of benzyl isothiocyanate in hepatocellular carcinoma |
| - | in-vitro, | adrenal, | SK-HEP-1 | - | in-vitro, | Liver, | HUH7 |
| 9170- | BITC, | p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expression |
| - | in-vitro, | BC, | MCF7 |
| 9171- | BITC, | Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 9172- | BITC, | Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling |
| - | in-vitro, | Pca, | PC3 |
| 9175- | BITC, | PEITC, | AITC, | Isothiocyanates in medicine: A comprehensive review on phenylethyl-, allyl-, and benzyl-isothiocyanates |
| - | Review, | Nor, | NA |
| - | Study, | UTI, | NA |
| 9178- | BITC, | Benzyl isothiocyanates modulate inflammation, oxidative stress, and apoptosis via Nrf2/HO-1 and NF-κB signaling pathways on indomethacin-induced gastric injury in rats |
| - | in-vivo, | Nor, | NA |
| 9179- | BITC, | Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma |
| - | in-vitro, | Melanoma, | NA |
| 9181- | BITC, | Benzyl isothiocyanate suppresses development and metastasis of murine mammary carcinoma by regulating the Wnt/β-catenin pathway |
| - | vitro+vivo, | BC, | 4T1 |
| 9182- | BITC, | Benzyl isothiocyanate (BITC) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer CAR cells |
| - | in-vitro, | Oral, | NA |
| 9184- | BITC, | Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate |
| - | vitro+vivo, | BC, | NA |
| 9185- | BITC, | PEITC, | AITC, | ITCs, | Effects of Brassicaceae Isothiocyanates on Prostate Cancer |
| - | Review, | Pca, | NA |
| 9186- | BITC, | Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest |
| - | vitro+vivo, | Pca, | NA |
| 9187- | BITC, | Bioavailability and metabolism of benzyl glucosinolate in humans consuming Indian cress (Tropaeolum majus L.) |
| - | Study, | Nor, | NA |
| 9189- | ITCs, | PEITC, | SFN, | BITC, | CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B | - | vitro+vivo, | Pca, | PC3 |
| 9194- | ITCs, | SFN, | BITC, | Erucin and benzyl isothiocyanate suppress growth of late stage primary human ovarian carcinoma cells and telomerase activity in vitro |
| - | in-vitro, | Ovarian, | NA |
| 9193- | ITCs, | PEITC, | BITC, | SFN, | Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research |
| - | Review, | Var, | NA |
| 9191- | ITCs, | AITC, | BITC, | PEITC, | SFN | Molecular Targets of Isothiocyanates in Cancer: Recent Advances |
| - | Review, | Var, | NA |
| 9230- | ITCs, | AITC, | BITC, | PEITC, | SFN | Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell Death |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:530 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid